Pharmaceutical

BioAge secures $170m for obesity therapeutics development

BioAge Labs has secured $170m in an Series D funding round to progress the development of therapeutics for obesity and metabolic diseases.

Feb 14, 2024 - 18:00
BioAge secures $170m for obesity therapeutics development
BioAge Labs has secured $170m in an Series D funding round to progress the development of therapeutics for obesity and metabolic diseases.
Read the original article

Tags:

Previous Article

FDA grants fast track status to Edgewise’s Duchenne treatment

Next Article

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: From drug shortages to high prices, U.S. system’s shortcomings have deep roots

STAT+: From drug shortages to high prices, U.S. system’...

Aug 15, 2023

Avalyn raises $175m in funding to develop inhaled IPF drugs

Avalyn raises $175m in funding to develop inhaled IPF d...

Sep 27, 2023

STAT+: AAFP’s CEO on how to keep primary care doctors in the field

STAT+: AAFP’s CEO on how to keep primary care doctors i...

Dec 23, 2023